Novel ADP-ribosyl cyclase and inhibitor thereof

• Main Authors: NAM, Tae-Sik, KIM, Uh-Hyun
• Format: Patent
• Language: English
• Published: 17.02.2022
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; COMPOSITIONS THEREOF; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PROCESSES OF PREPARING SUCH COMPOSITIONS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The present invention relates to a pharmaceutical composition comprising an inhibitor against the expression or activation of novel ADP-ribosyl cyclase or a naturally occurring mutant thereof as an active ingredient for preventing or treating an ADP-ribosyl cyclase-mediated disease. In addition, the present invention relates to a composition for diagnosis of an ADP-ribosyl cyclase-mediated disease, the composition comprising an agent for measuring a gene expression level or protein level of the ADP-ribosyl cyclase or a naturally occurring mutant thereof. The composition of the present invention has the effect of inhibiting the calcium increase in splenocytes, which is attributed to angiotensin II-induced ADP-ribosyl cyclase expression or activation, and as such can be advantageously used as a therapeutic agent for ADP-ribosyl cyclase-mediated diseases, particularly a renal disease.